IC-OS Weekly Webinar - Cardiac Computed Tomographic Imaging in Cardio-Oncology: An Expert Consensus Statement from the Society of Cardiovascular Computed Tomography

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Dr. Eric Yang currently serves as an Associate Clinical Professor of Medicine at the University of California at Los Angeles, where he has served as clinical faculty since 2011. He obtained his medical degree at the University of Illinois at Chicago College of Medicine, and underwent residency and fellowship training at Harbor-UCLA Medical Center, where he also served as chief fellow. Dr. Yang is the Founder and Director of the UCLA Cardio-oncology Program which was formally established in 2016. The mission of this program is to provide high quality, multidisciplinary clinical cardiovascular care to the cancer population of UCLA Health to patients either at risk for, or who have developed short and long-term cardiotoxicity from both historical and modern cancer therapies. In 2022, the UCLA Cardio-Oncology Program was designated an International Cardio-Oncology Society Center of Excellence, Gold Tier, in its inaugural selection process. Dr. Yang’s research interests are focused on the mechanistic cross talk of how the biological effects of cancer and/or cancer treatment-associated cardiotoxicity may yield insights into the development of traditional cardiovascular disease, including atherosclerotic disease, heart failure, arrhythmias, and hypertension. He is also focusing on exploring effective diagnostic and pharmacologic treatment strategies as an investigator in both national and international based registries of immune checkpoint associated myocarditis and chimeric antigen T-cell receptor therapy related cardiotoxicity. He is also active in evaluating both short- and long-term cardiovascular effects of treatments in cancer survivors, including those with autonomic dysfunction and those who have received high risk chemoradiation treatments. Dr. Yang has served on National Cardio-oncology Committees within the American College of Cardiology and the American Heart Association. He also is involved with the National Comprehensive Cancer Network Survivorship Panel and serves on the inaugural editorial board of JACC: Cardio-Oncology, one of the first major cardiology journals dedicated to the science of Cardio-Oncology. Since joining UCLA, Dr. Yang has also been heavily involved in medical education, where he serves as Associate Program Director of the UCLA-Olive View-West LA VA Cardiovascular Diseases Fellowship. He is also a team member of the structural heart program, where he is involved with cardiovascular imaging of the team’s interventional percutaneous procedures (ie TAVR, Mitraclip, etc). His clinical interests include cardio-oncology, cardiac imaging, medical education, valvular disease, and hemodynamics.

Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.

Juan C. Lopez-Mattei, MD, FACC, FASE, FSCCT, FSCMR is the co-director and co-founder of Cardiac Radiology Services at University of Texas MD Anderson Cancer Center, a comprehensive cardiac imaging center of excellence consisting of a Cardiac CT/MRI service dedicated to cancer patients and survivors. He is an associate professor of Medicine and Radiology at University of Texas MD Anderson Cancer Center. Dr. Lopez-Mattei is a nationally recognized expert, with over 80 peer-reviewed publications in the fields of cardio-oncology, echocardiography, cardiovascular computed tomography and cardiovascular magnetic resonance. He holds multiple leadership positions in cardiovascular imaging societies such as American Society of Echocardiography, Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. In addition, Dr. Lopez-Mattei was elected to the American College of Cardiology Emerging Faculty Leadership Academy in 2019 , to the American Society of Echocardiography’s Leadership Academy in 2020 and in 2021 he was elected as member of American College of Cardiology CV Imaging Section Leadership Council. He is also a member of the Certification Board of Cardiovascular Magnetic Resonance (CBCMR) Assessment Committee and a member of the editorial boards of Journal of Cardiovascular Magnetic Resonance and JACC: Cardio-Oncology. He trained as a general cardiologist in Puerto Rico and pursued further training in cardiovascular imaging at Houston Methodist Hospital and is currently qualified as level 3 in echocardiography, cardiac CT and Cardiac MRI.

Maros Ferencik MD, PhD, MCR, MSCCT graduated from the medical school at Comenius University in Bratislava, Slovakia. He completed his clinical and research training in internal medicine, cardiology, and advanced cardiac imaging (cardiac CT, echocardiography, cardiac MR, and nuclear cardiology) at the Massachusetts General Hospital (MGH) and Harvard Medical School. After completion of training, he joined the faculty of Knight Cardiovascular Institute at Oregon Health & Science University where he is an Associate Professor of Medicine, Section Head of Cardiovascular Imaging, and Director of Cardio-Oncology Program. Dr. Ferencik’s research focuses on the effective and efficient use of cardiac CT in the assessment of coronary atherosclerosis and coronary artery disease. He has participated in the evaluation and assessment of cardiac CT in large multicenter clinical trials (ROMICAT I and II, PROMISE, Framingham Heart Study) with the focus on detection and characterization of high-risk coronary atherosclerosis, assessment of coronary calcium, improvement of the diagnostic accuracy of CT for the diagnosis of ACS and prognosis of future cardiovascular events. He has served on the Board of Directors and Executive Committee of the Society of Cardiovascular Tomography and as an Associate Editor of the Journal of Cardiovascular Computed Tomography. He currently serves as the Vice-President and Chair of the Education Committee.